(1) Schirren J, Schirren M, Lampl L, Sponholz S. Surgery for pulmonary metastases: quo vadis? Eur J Cardiothorac Surg 2017 Mar 1;51(3):408-10.
(2) Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med 2010 Feb;103(2):60-6.
(3) Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49.
(4) Aberg T, Malmberg KA, Nilsson B, Nou E. The effect of metastasectomy: fact or fiction? Ann Thorac Surg 1980 Oct;30(4):378-84.
(5) Barton MK. Metastasectomy on the rise across several cancer types. CA Cancer J Clin 2015 May;65(3):163-4.
(6) Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR, et al. The rise in metastasectomy across cancer types over the past decade. Cancer 2015 Mar 1;121(5):747-57.
(7) Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol 2015 Sep 1;1(6):787-95.
(8) Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013 Feb;20(2):572-9.
(9) Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2016 Nov 24;11:CD002200.
(10) Mokhles S, Macbeth F, Farewell V, Fiorentino F, Williams NR, Younes RN, et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg 2016 Sep;103(10):1259-68.
(11) Aberg T. Selection mechanisms as major determinants of survival after pulmonary metastasectomy. Ann Thorac Surg 1997 Mar;63(3):611-2.
(12) Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007 Feb 17;334(7589):349-51.
(13) Monson K, Treasure T, Brew-Graves C, Jenkins V, Fallowfield L. Surveying patients' views on trial information provision and decision making using the 'Accept/Decline' clinical trials questionnaire. Trials 2017;18 (Suppl 1):24.
(14) Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 Jul;34(3 Suppl 2):13-9.
(15) Cella D. FACIT questionnaire specifics manual. 24-8-2005. 24-8-2005.
Ref Type: Pamphlet
(16) Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992 Sep;31 ( Pt 3):301-6.
(17) van Reenan M, Janssen B. Euro - a new facility for the measurement of health-related quality of life. Health Policy 2015;16(3):13-22.
(18) Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 2018;73(1):13-22.
(19) Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009 Jan;12(1):124-9.
(20) Eton D, Yost K. Minimally important differences on the functional assessment of chronic illness therapy instruments. In FACIT Manual Version 4. Section 4 - Validity and Interpretation. Doc 116. 2005. 2005.
Ref Type: Pamphlet
(21) Cox DR. Regression models and life-table. Journal of the Royal Statistical Society B 1972;34:187-220.
(22) Farewell DM. Marginal analyses of longitudinal data with an informative pattern of observations. Biometrika 2010;97(1):65-78.
(23) Fiorentino F, Treasure T. A plea for consistency in the reporting of surgical series illustrated with an analysis of 51 follow-up reports of pulmonary metastasectomy in colorectal carcinoma. J Thorac Oncol 2010 Jun;5(6 Suppl 2):S192-S195.
(24) Gyawali B, Shimokata T, Honda K, Ando Y. Reporting harms more transparently in trials of cancer drugs. BMJ 2018 Nov 1;363:k4383.
(25) Treasure T, Baum M. An approach to randomization into surgical clinical trials. Br J Surg 2017 Jan;104(1):11-2.
(26) Prasad V, Cifu A. Ending Medical Reversal: Improving Outcomes, Saving Lives. Baltimore: Johns Hopkins University Press; 2015.
(27) Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013 Aug;88(8):790-8.
(28) Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981 Jul 2;305(1):6-11.
(29) Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011 Aug;12(8):763-72.
(30) Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015 Jun;16(6):630-7.
(31) Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL. Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 2006 Mar;17(3):457-60.
(32) Donovan JL, de S, I, Toerien M, Paramasivan S, Hamdy FC, Blazeby JM. The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. J Clin Epidemiol 2014 Aug;67(8):912-20.
(33) Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials 2016 Jun 8;17(1):283.
(34) Mills N, Gaunt D, Blazeby JM, Elliott D, Husbands S, Holding P, et al. Training health professionals to recruit into challenging randomized controlled trials improved confidence: the development of the QuinteT randomized controlled trial recruitment training intervention. J Clin Epidemiol 2018 Mar;95:34-44.
(35) Rooshenas L, Scott LJ, Blazeby JM, Rogers CA, Tilling KM, Husbands S, et al. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. J Clin Epidemiol 2019 Feb;106:108-20.
(36) Belderbos J. Hunting a ghost for 25 years - Will We Ever Catch OMD 'Yes'. 2019 p. 12-3.
(37) Wright G. NSCL OMD is defined by a fixed maximum number of metastases, not technical reasons of local treatment . 2019 p. 13-4.
(38) Treasure T. Hunting a ghost for 25 years - Will We Ever Catch OMD 'No'. 2019 p. 12.
(39) Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019 May 18;393(10185):2051-8.
(40) Lewis SL, Porceddu S, Nakamura N, Palma DA, Lo SS, Hoskin P, et al. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol 2017 Aug;40(4):418-22.
(41) Mukherjee S. A Radical Idea in "The Emperor of All Maladies". The Emperor of the Maladies.New York: Scribner; 2010. p. 60-72.
(42) Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985 Mar 14;312(11):665-73.